These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11323007)

  • 1. Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys.
    Oikawa K; Kamimura H; Watanabe T; Miyamoto I; Higuchi S
    Thromb Res; 2001 Mar; 101(6):493-500. PubMed ID: 11323007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of drug disposition between wild-type and novel tissue-type plasminogen activator pamiteplase in rats.
    Oikawa K; Watanabe T; Higuchi S
    Drug Metab Dispos; 2000 Sep; 28(9):1087-93. PubMed ID: 10950854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination, pharmacokinetics and protein binding of a novel tissue-type plasminogen activator, pamiteplase in human plasma.
    Oikawa K; Watanabe T; Miyamoto I; Higuchi S
    Xenobiotica; 2000 Oct; 30(10):993-1003. PubMed ID: 11315107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research and development of novel modified tissue-type plasminogen activator (t-PA), pamiteplase].
    Katoh M; Hayamizu K
    Nihon Yakurigaku Zasshi; 2000 Apr; 115(4):237-43. PubMed ID: 10876808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of receptor-mediated endocytosis kinetics between wild-type t-PA and recombinant pamiteplase in isolated rat hepatocytes and liver cell plasma membranes.
    Oikawa K; Watanabe T; Higuchi S
    Xenobiotica; 2000 Jul; 30(7):693-705. PubMed ID: 10963060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and thrombolytic properties of unglycosylated recombinant tissue-type plasminogen activator (BM 06.021) produced in Escherichia coli.
    Martin U; Fischer S; Kohnert U; Opitz U; Rudolph R; Sponer G; Stern A; Strein K
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jul; 346(1):108-13. PubMed ID: 1407000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of recombinant double-chain t-PA (duteplase): effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction.
    Koster RW; Cohen AF; Kluft C; Kasper FJ; van der Wouw PA; Weatherley BC
    Clin Pharmacol Ther; 1991 Sep; 50(3):267-77. PubMed ID: 1914361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens.
    Eppler S; Senn T; Gilkerson E; Modi NB
    Biopharm Drug Dispos; 1998 Jan; 19(1):31-8. PubMed ID: 9510983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion.
    Fong KL; Crysler CS; Mico BA; Boyle KE; Kopia GA; Kopaciewicz L; Lynn RK
    Drug Metab Dispos; 1988; 16(2):201-6. PubMed ID: 2898333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):834-40. PubMed ID: 7509901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction.
    Modi NB; Fox NL; Clow FW; Tanswell P; Cannon CP; Van de Werf F; Braunwald E
    J Clin Pharmacol; 2000 May; 40(5):508-15. PubMed ID: 10806604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of infarction volume by bolus injection of pamiteplase, a modified tissue plasminogen activator with a longer half-life.
    Suzuki Y; Kano T; Katayama Y; Tejima E; Harada T
    Neurol Res; 2003 Jul; 25(5):477-80. PubMed ID: 12866195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat.
    Larsen GR; Metzger M; Henson K; Blue Y; Horgan P
    Blood; 1989 May; 73(7):1842-50. PubMed ID: 2496774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single and repeated intravenous toxicity studies of pamiteplase (genetical recombination) in rats and monkeys.
    Ishikawa A; Ohata T; Imamura K; Iwasaki M; Sakai T; Matsuzawa T; Okazaki S
    J Toxicol Sci; 1997 May; 22(2):117-33. PubMed ID: 9198009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
    Bae SK; Lee SJ; Kim YG; Kim SH; Kim JW; Kim T; Lee MG
    Biopharm Drug Dispos; 2005 Apr; 26(3):99-115. PubMed ID: 15723427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of pamiteplase, a modified t-PA, in a rat model of embolic stroke.
    Sumii T; Singhal AB; Asahi M; Shimizu-Sasamata M; Suzuki M; Miyata K; Lo EH
    Neuroreport; 2001 Mar; 12(3):615-8. PubMed ID: 11234775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo kinetics of 99mTc labeled recombinant tissue plasminogen activator in rabbits.
    Itoh K; Ieko M; Hiraguchi E; Kitayama H; Tsukamoto E
    Ann Nucl Med; 1994 Aug; 8(3):193-9. PubMed ID: 7811562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.